BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 19228741)

  • 1. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
    Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
    Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
    Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
    J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
    Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
    Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Kurahashi T; Miyake H; Hara I; Fujisawa M
    J Urol; 2007 Feb; 177(2):757-61. PubMed ID: 17222676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer.
    Prtilo A; Leach FS; Markwalder R; Kappeler A; Burkhard FC; Cecchini MG; Studer UE; Thalmann GN
    J Urol; 2005 Nov; 174(5):1814-8; discussion 1818. PubMed ID: 16217293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
    Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MT1G hypermethylation is associated with higher tumor stage in prostate cancer.
    Henrique R; Jerónimo C; Hoque MO; Nomoto S; Carvalho AL; Costa VL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1274-8. PubMed ID: 15894685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation of the ASC gene promoter is associated with aggressive prostate cancer.
    Collard RL; Harya NS; Monzon FA; Maier CE; O'Keefe DS
    Prostate; 2006 May; 66(7):687-95. PubMed ID: 16425203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis.
    Diallo JS; Aldejmah A; Mouhim AF; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
    BJU Int; 2008 May; 101(10):1302-9. PubMed ID: 18294307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer.
    Haldrup C; Mundbjerg K; Vestergaard EM; Lamy P; Wild P; Schulz WA; Arsov C; Visakorpi T; Borre M; Høyer S; Orntoft TF; Sørensen KD
    J Clin Oncol; 2013 Sep; 31(26):3250-8. PubMed ID: 23918943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms.
    Morote J; Del Amo J; Borque A; Ars E; Hernández C; Herranz F; Arruza A; Llarena R; Planas J; Viso MJ; Palou J; Raventós CX; Tejedor D; Artieda M; Simón L; Martínez A; Rioja LA
    J Urol; 2010 Aug; 184(2):506-11. PubMed ID: 20620409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.
    Cottrell S; Jung K; Kristiansen G; Eltze E; Semjonow A; Ittmann M; Hartmann A; Stamey T; Haefliger C; Weiss G
    J Urol; 2007 May; 177(5):1753-8. PubMed ID: 17437806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer.
    Asatiani E; Huang WX; Wang A; Rodriguez Ortner E; Cavalli LR; Haddad BR; Gelmann EP
    Cancer Res; 2005 Feb; 65(4):1164-73. PubMed ID: 15734999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
    Fleischmann A; Schlomm T; Huland H; Köllermann J; Simon P; Mirlacher M; Salomon G; Chun FH; Steuber T; Simon R; Sauter G; Graefen M; Erbersdobler A
    Clin Cancer Res; 2008 Dec; 14(23):7838-42. PubMed ID: 19047112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy.
    Hirata H; Hinoda Y; Kikuno N; Suehiro Y; Shahryari V; Ahmad AE; Tabatabai ZL; Igawa M; Dahiya R
    J Urol; 2009 Apr; 181(4):1907-12. PubMed ID: 19237173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens.
    Whittemore DE; Hick EJ; Carter MR; Moul JW; Miranda-Sousa AJ; Sexton WJ
    J Urol; 2008 Feb; 179(2):516-22; discussion 522. PubMed ID: 18076949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy.
    Bastian PJ; Ellinger J; Heukamp LC; Kahl P; Müller SC; von Rücker A
    Eur Urol; 2007 Mar; 51(3):665-74; discussion 674. PubMed ID: 16956712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels.
    Haldrup C; Lynnerup AS; Storebjerg TM; Vang S; Wild P; Visakorpi T; Arsov C; Schulz WA; Lindberg J; Grönberg H; Egevad L; Borre M; Ørntoft TF; Høyer S; Sørensen KD
    Mol Oncol; 2016 Jun; 10(6):825-37. PubMed ID: 26905753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.